How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

29,050 results for

Immunotherapy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Cancer Immunotherapy After Adjuvant Immunotherapy: Clinical Effectiveness and Guidelines

Cancer Immunotherapy After Adjuvant Immunotherapy: Clinical Effectiveness and Guidelines Cancer Immunotherapy After Adjuvant Immunotherapy: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Cancer Immunotherapy After Adjuvant Immunotherapy: Clinical Effectiveness and Guidelines Cancer Immunotherapy After Adjuvant Immunotherapy: Clinical Effectiveness and Guidelines Last updated: August 1, 2019 Project Number: RA1056-000 Product Line: Research Type: Drug Report Type

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

2. Oral Immunotherapy for Food Oral Immunotherapy Protocols for Food Allergy in Infants and Children: Comparative Clinical Effectiveness

Oral Immunotherapy for Food Oral Immunotherapy Protocols for Food Allergy in Infants and Children: Comparative Clinical Effectiveness Oral Immunotherapy for Food Oral Immunotherapy Protocols for Food Allergy in Infants and Children: Comparative Clinical Effectiveness | CADTH.ca Find the information you need Oral Immunotherapy for Food Oral Immunotherapy Protocols for Food Allergy in Infants and Children: Comparative Clinical Effectiveness Oral Immunotherapy for Food Oral Immunotherapy Protocols (...) for Food Allergy in Infants and Children: Comparative Clinical Effectiveness Last updated: November 2, 2018 Project Number: RB1272-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of oral immunotherapy (OIT) for food allergy in children? Key Message Six randomized controlled trials and two non-randomized studies were identified regarding the clinical effectiveness of oral immunotherapy (OIT) for food

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

3. Anti-GD2 antibody-containing immunotherapy postconsolidation therapy for people with high-risk neuroblastoma treated with autologous haematopoietic stem cell transplantation. (PubMed)

Anti-GD2 antibody-containing immunotherapy postconsolidation therapy for people with high-risk neuroblastoma treated with autologous haematopoietic stem cell transplantation. Neuroblastoma is a rare malignant disease that primarily affects children. The tumours mainly develop in the adrenal medullary tissue, and an abdominal mass is the most common presentation. High-risk disease is characterised by metastasis and other primary tumour characteristics resulting in increased risk for an adverse (...) outcome. The GD2 carbohydrate antigen is expressed on the cell surface of neuroblastoma tumour cells and is thus a promising target for anti-GD2 antibody-containing immunotherapy.To assess the efficacy of anti-GD2 antibody-containing postconsolidation immunotherapy after high-dose chemotherapy (HDCT) and autologous haematopoietic stem cell transplantation (HSCT) compared to standard therapy after HDCT and autologous HSCT in people with high-risk neuroblastoma. Our primary outcomes were overall

2019 Cochrane

4. Oral and sublingual immunotherapy for egg allergy. (PubMed)

Oral and sublingual immunotherapy for egg allergy. Clinical egg allergy is a common food allergy. Current management relies upon strict allergen avoidance. Oral immunotherapy might be an optional treatment, through desensitization to egg allergen.To determine the efficacy and safety of oral and sublingual immunotherapy in children and adults with immunoglobulin E (IgE)-mediated egg allergy as compared to a placebo treatment or an avoidance strategy.We searched 13 databases for journal articles (...) , conference proceedings, theses and trials registers using a combination of subject headings and text words (last search 31 March 2017).We included randomized controlled trials (RCTs) comparing oral immunotherapy or sublingual immunotherapy administered by any protocol with placebo or an elimination diet. Participants were children or adults with clinical egg allergy.We retrieved 97 studies from the electronic searches. We selected studies, extracted data and assessed the methodological quality. We

2018 Cochrane

6. Antigen-specific active immunotherapy for ovarian cancer. (PubMed)

Antigen-specific active immunotherapy for ovarian cancer. This is the second update of the review first published in the Cochrane Library (2010, Issue 2) and later updated (2014, Issue 9).Despite advances in chemotherapy, the prognosis of ovarian cancer remains poor. Antigen-specific active immunotherapy aims to induce tumour antigen-specific anti-tumour immune responses as an alternative treatment for ovarian cancer.Primary objective• To assess the clinical efficacy of antigen-specific active (...) immunotherapy for the treatment of ovarian cancer as evaluated by tumour response measured by Response Evaluation Criteria In Solid Tumors (RECIST) and/or cancer antigen (CA)-125 levels, response to post-immunotherapy treatment, and survival differences◦ In addition, we recorded the numbers of observed antigen-specific humoral and cellular responsesSecondary objective• To establish which combinations of immunotherapeutic strategies with tumour antigens provide the best immunological and clinical results

2018 Cochrane

7. ASCIA Guide - Venom Immunotherapy

ASCIA Guide - Venom Immunotherapy ASCIA Venom Immunotherapy Guide 1 Venom Immunotherapy A Guide for Clinical Immunology/Allergy Specialists This document supersedes information contained in the older 2014 ASCIA Allergen Immunotherapy Manual. It has been updated by the ASCIA Immunotherapy Working Party and extracted into this separate Guide. ASCIA Immunotherapy Working Party members are listed on the ASCIA website. ASCIA resources are based on published literature and expert review. ASCIA health (...) professional document references are at www.allergy.org.au/hp/papers Abbreviations CCD Common carbohydrate determinants GMP Good manufacturing practice IDT Intradermal test IgE Immunoglobulin E IgG Immunoglobulin G JJA Jack Jumper Ant MCT Mast cell tryptase PBS Pharmaceutical Benefits Scheme, AU Pharmac Pharmaceutical Management Agency, NZ QOL Quality of life SCIT Subcutaneous immunotherapy sIgE (allergen) specific IgE SPT Skin prick test SR Systemic reactions TGA Therapeutic Goods Administration, AU VIT

2019 Australasian Society of Clinical Immunology and Allergy

8. ASCIA Guide - Aeroallergen Immunotherapy

ASCIA Guide - Aeroallergen Immunotherapy Aeroallergen Immunotherapy A Guide for Clinical Immunology/Allergy Specialists This document supersedes information contained in the 2015 ASCIA Allergen Immunotherapy Manual. It has been updated by the ASCIA Immunotherapy Working Party and extracted into this separate Guide. ASCIA Immunotherapy Working Party members are listed on the ASCIA website www.allergy.org.au/members/committees#wpim ASCIA resources are based on published literature and expert (...) review. ASCIA health professional document references are at www.allergy.org.au/hp/papers Abbreviations AIT Allergen immunotherapy LLR Large local reaction AlOH Aluminium hydroxide (Alum) MCT Mast cell tryptase AR Adverse reaction NSP Normal saline with phenol BAT Basophil activation tests PBS Pharmaceutical Benefits Scheme, AU CCD Common carbohydrate determinants Pharmac Pharmaceutical Management Agency, NZ DBPC Double blind placebo controlled PRP Pathogenesis-related protein DF Dermatophagoides

2019 Australasian Society of Clinical Immunology and Allergy

9. Oral Immunotherapy for Food Allergy in Infants and Children: Clinical Effectiveness, Cost-Effectiveness and Guidelines

Oral Immunotherapy for Food Allergy in Infants and Children: Clinical Effectiveness, Cost-Effectiveness and Guidelines Oral Immunotherapy for Food Allergy in Infants and Children: Clinical Effectiveness, Cost-Effectiveness and Guidelines | CADTH.ca Find the information you need Oral Immunotherapy for Food Allergy in Infants and Children: Clinical Effectiveness, Cost-Effectiveness and Guidelines Oral Immunotherapy for Food Allergy in Infants and Children: Clinical Effectiveness, Cost (...) -Effectiveness and Guidelines Last updated: October 4, 2018 Project Number: RB1264-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of oral immunotherapy for food allergy in children? What is the cost-effectiveness of oral immunotherapy for food allergy in children? Key Message Three systematic reviews with meta-analyses, thirteen randomized-controlled studies, one economic evaluation, and three evidence

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

10. NY-ESO-1 T-Cell Immunotherapy for Recurrent or Refractory Ovarian Cancer: Clinical Effectiveness

NY-ESO-1 T-Cell Immunotherapy for Recurrent or Refractory Ovarian Cancer: Clinical Effectiveness NY-ESO-1 T-Cell Immunotherapy for Recurrent or Refractory Ovarian Cancer: Clinical Effectiveness | CADTH.ca Find the information you need NY-ESO-1 T-Cell Immunotherapy for Recurrent or Refractory Ovarian Cancer: Clinical Effectiveness NY-ESO-1 T-Cell Immunotherapy for Recurrent or Refractory Ovarian Cancer: Clinical Effectiveness Last updated: November 15, 2018 Project Number: RA0989-000 Product (...) Line: Research Type: Drug Report Type: Reference List Result type: Report Question What is the clinical effectiveness of NY-ESO T-cell immunotherapy in adults with recurrent or refractory ovarian cancer? Key Message No relevant literature was identified regarding the clinical effectiveness of NY-ESO T-cell immunotherapy in adults with recurrent or refractory ovarian cancer. Files Rapid Response Reference List Published : November 15, 2018 Related Content Follow us: © 2019 Canadian Agency for Drugs

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

11. The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches (PubMed)

The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches The immune system plays a fundamental role in preventing cancer development by recognising and eliminating tumour cells. The recent success in the field of immunotherapy has confirmed the potential to exploit the immune response as a cancer treatment. Head and neck squamous cell carcinoma (HNSCC) is a malignancy characterized by dismal prognosis and high mortality rate; low survival (...) outcomes in combination with significant toxicity of current treatment strategies highlight the necessity for novel therapeutic modalities. HNSCC is a favourable disease for immunotherapy, as immune escape plays a key role in tumour initiation and progression. T-cell checkpoint inhibitors targeting programmed cell death protein-1 have emerged as novel immunotherapy agents showing remarkable efficacy in HNSCC. However, only a minority of patients derive benefit for single-agent immunotherapies

Full Text available with Trip Pro

2017 ESMO open

12. Tolerability of an Immunologically Enhanced Subcutaneous Immunotherapy Preparation in Patients Treated with Concomitant Allergy Immunotherapy: A Non-Interventional Observational Study (PubMed)

Tolerability of an Immunologically Enhanced Subcutaneous Immunotherapy Preparation in Patients Treated with Concomitant Allergy Immunotherapy: A Non-Interventional Observational Study For causal treatment by allergy immunotherapy (AIT) a single or few allergen products for the clinically most relevant allergens are applied to treat multiple allergies, but few data on the tolerability of multiple AIT applications are available.The aim of our study was to investigate safety and tolerability (...) in patients treated by subcutaneous immunotherapy (SCIT) and concomitant SCIT or sublingual immunotherapy (SLIT) products.In a non-interventional, observational study in Germany treatment of patients with a primary SCIT and concomitant AIT (SCIT or SLIT) was documented during the first 4 months of treatment. Adverse events (AEs) were recorded by the physicians and by patients in diaries, and coded using the Medical Dictionary for Regulatory Activities (MedDRA).Three hundred and seven patients were treated

Full Text available with Trip Pro

2017 Drugs - real world outcomes

13. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent. (PubMed)

Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent. Non-small cell lung cancer (NSCLC) is the most common lung cancer, accounting for approximately 80% to 85% of all cases. For patients with localised NSCLC (stages I to III), it has been speculated that immunotherapy may be helpful for reducing postoperative recurrence rates, or improving the clinical outcomes of current treatment (...) for unresectable tumours. While several new agents have now entered phase III clinical trials, we felt a systematic review was needed to address the question of the effectiveness and safety of immunotherapy in patients with stages I to III NSCLC.To evaluate the effectiveness and safety of immunotherapy (excluding checkpoint inhibitors) in patients with localised NSCLC (stages I to III) who received surgery or radiotherapy with curative intent.We searched the following databases (from inception to 20 January

2017 Cochrane

14. Immunotherapy for diabetic amyotrophy. (PubMed)

Immunotherapy for diabetic amyotrophy. People with diabetes mellitus (DM) sometimes present with acute or subacute, progressive, asymmetrical pain and weakness of the proximal lower limb muscles. The various names for the condition include diabetic amyotrophy, diabetic lumbosacral radiculoplexus neuropathies, diabetic femoral neuropathy or Bruns-Garland syndrome. Some studies suggest that diabetic amyotrophy may be an immune-mediated inflammatory microvasculitis causing ischaemic damage (...) of the nerves. Immunotherapies would therefore be expected to be beneficial. This is the second update of a review first published in 2009.To review the evidence from randomised trials for the efficacy of any form of immunotherapy in the treatment of diabetic amyotrophy.On 5 September 2016 we searched the Cochrane Neuromuscular Specialised Register, CENTRAL, MEDLINE and Embase. We also contacted authors of relevant publications and other experts to obtain additional references, unpublished trials

Full Text available with Trip Pro

2017 Cochrane

15. Immunotherapy for metastatic renal cell carcinoma. (PubMed)

Immunotherapy for metastatic renal cell carcinoma. Since the mid-2000s, the field of metastatic renal cell carcinoma (mRCC) has experienced a paradigm shift from non-specific therapy with broad-acting cytokines to specific regimens, which directly target the cancer, the tumour microenvironment, or both.Current guidelines recommend targeted therapies with agents such as sunitinib, pazopanib or temsirolimus (for people with poor prognosis) as the standard of care for first-line treatment (...) of people with mRCC and mention non-specific cytokines as an alternative option for selected patients.In November 2015, nivolumab, a checkpoint inhibitor directed against programmed death-1 (PD-1), was approved as the first specific immunotherapeutic agent as second-line therapy in previously treated mRCC patients.To assess the effects of immunotherapies either alone or in combination with standard targeted therapies for the treatment of metastatic renal cell carcinoma and their efficacy to maximize

Full Text available with Trip Pro

2017 Cochrane

16. Adoptive immunotherapy using genetically modified lymphocytes for lymphoproliferative disorders or hematological malignancies

Adoptive immunotherapy using genetically modified lymphocytes for lymphoproliferative disorders or hematological malignancies Adoptive immunotherapy using genetically modified lymphocytes for lymphoproliferative disorders or hematological malignancies Adoptive immunotherapy using genetically modified lymphocytes for lymphoproliferative disorders or hematological malignancies HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment from a member (...) of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Adoptive immunotherapy using genetically modified lymphocytes for lymphoproliferative disorders or hematological malignancies. Lansdale: HAYES, Inc. Directory Publication. 2017 Authors' conclusions Rationale: CAR T cells and genetically engineered TCR T cells are targeted, personalized therapies for malignancies and other neoplastic disorders, including hematological cancers

2018 Health Technology Assessment (HTA) Database.

17. A randomised placebo-controlled trial investigating efficacy and mechanisms of low-dose intradermal allergen immunotherapy in treatment of seasonal allergic rhinitis

A randomised placebo-controlled trial investigating efficacy and mechanisms of low-dose intradermal allergen immunotherapy in treatment of seasonal allergic rhinitis A randomised placebo-controlled trial investigating efficacy and mechanisms of low-dose intradermal allergen immunotherapy in treatment of seasonal allergic rhinitis Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could (...) not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Low-dose intradermal immunotherapy for seasonal allergic rhinitis had no clinical effect even though it suppressed skin late responses to allergen. {{author}} {{($index , , , , , , , , , , , , & . Anna Slovick 1, 2 , Abdel Douiri 3 , Rachel Muir 4 , Andrea Guerra 1 , Konstantinos Tsioulos

2016 NIHR HTA programme

18. Cancer Immunotherapy: A Primer for Clinicians

Cancer Immunotherapy: A Primer for Clinicians Cancer Immunotherapy: A Primer for Clinicians – Clinical Correlations Search Cancer Immunotherapy: A Primer for Clinicians June 5, 2018 6 min read By Thatcher Heumann, MD Peer Reviewed The Next Big Thing For many physicians in training, navigating through the numerous anti-cancer agents and keeping pace with the latest treatments can be daunting. Major categories of systemic cancer treatments include chemotherapy (cytotoxic drugs that arrest (...) the cell cycle), hormonal therapy (drugs that inhibit hormone production or bind to ‘starve’ cancers that thrive off of estrogen/testosterone), and targeted therapy (small molecules or monoclonal antibodies that bind to intra/extracellular targets to block tumor angiogenesis/growth factor signal transduction, or mark cells for destruction). The latest treatment class, immunotherapy, has taken center stage in our national health dialogue particularly ”[1] Former President Jimmy Carter’s public diagnosis

2018 Clinical Correlations

19. The role of immunotherapy in IVF: a guideline

The role of immunotherapy in IVF: a guideline The role of immunotherapy in in vitro fertilization: a guideline Practice Committee of the American Society for Reproductive Medicine American Society for Reproductive Medicine, Birmingham, Alabama Adjuvant immunotherapy treatments in in vitro fertilization (IVF) aim to improve the outcome of assisted reproductive technology (ART) in both the general ART population as well as subgroups such as patients with recurrent miscarriage or implantation (...) to improved live-birth outcome. While some of these medica- tions (e.g., aspirin and corticosteroids) have been used for many years and are relatively low cost, others (e.g., intravenous fat emulsions and granu- locyte colony–stimulating factor [G- CSF]) are newer, of higher cost, and with risks that have been poorly char- acterized. It is imperative that physi- cians providing ART treatments have a full understanding of the potential risks and bene?ts associated with adjuvant immunotherapy in order

2018 Society for Assisted Reproductive Technology

20. New Oncologic Therapies Mean New Oncologic Emergencies: An Approach to Immunotherapy-Related Adverse Events

New Oncologic Therapies Mean New Oncologic Emergencies: An Approach to Immunotherapy-Related Adverse Events New Oncologic Therapies Mean New Oncologic Emergencies: An Approach to Immunotherapy-Related Adverse Events - CanadiEM New Oncologic Therapies Mean New Oncologic Emergencies: An Approach to Immunotherapy-Related Adverse Events In , by Arden Azim October 30, 2018 A 63-year-old man, Andrew, presents to the emergency department with a several-day history of worsening diarrhea. He has (...) review his medications you see his cancer drug “ipilimumab.” A quick search on UpToDate describes it as an “immunotherapy medication” – you’re not familiar with this class of medication and wonder if it might affect your work-up and management strategy. Oncology patients often present to the ED acutely ill with complications of their cancer treatment. Approaches to common complications of chemotherapy like febrile neutropenia are well-established among ED clinicians. However, newer classes of anti

2018 CandiEM

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>